Article Text

Download PDFPDF
Narrowing the gap: access to HIV treatments in developing countries. A pharmaceutical company's perspective
  1. James Cochrane
  1. Glaxo Wellcome plc, Greenford, UK


    The advent of new antiretroviral medicines means that the effects of HIV can now be curbed, but only one in twenty infected people have so far benefited. For those living in developing countries, the new treatments are practically unattainable. Governments, UNAIDS and pharmaceutical companies recognise this only too well and have rethought established assumption in order to try and overcome the challenges posed by cost, inadequate health services and unreliable local supply of medicines.

    • AIDS
    • treatment gap
    • developing countries
    • Glaxo Wellcome
    • access to medicines
    • public health

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


    • James Cochrane is Executive Director, Europe, the Middle East and Africa, Glaxo Wellcome plc, Greenford, Middlesex.

    Other content recommended for you